GlassScriptPhysician profile
William J Gibbons
NPI 1215042700
$4,586.96
in general payments reported to CMS, 2019-2025
22 companies · $457 in 2025
The $457 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $308 · 2021: $465 · 2022: $712 · 2023: $1,133 · 2024: $694 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,696 · Consulting Fee: $400 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.69 |
| Consulting Fee | $400.00 |
| Education | $188.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,497.10 | 2019-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $677.86 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $590.84 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.52 | 2019-2025 | Ofev |
| Janssen Pharmaceuticals, INC | $304.93 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $166.89 | 2020-2023 | Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $165.98 | 2021-2023 | |
| Insmed, INC. | $153.82 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $108.07 | 2023-2025 | Winrevair |
| Gilead Sciences, INC. | $73.01 | 2019 | |
| Kestra Medical Technology Services, INC. | $64.87 | 2022-2025 | Assure Wcd |
| Takeda Pharmaceuticals U.S.A., INC. | $57.94 | 2023-2024 | Glassia, Aralast |
| United Therapeutics Corporation | $56.76 | 2021-2025 | Tyvaso |
| Alexion Pharmaceuticals, INC. | $41.47 | 2019 | |
| Alnylam Pharmaceuticals INC. | $39.00 | 2024-2025 | Onpattro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $38.68 | 2022-2024 | Hillrom - Life 2000 Ventilation System |
| Cvrx, INC. | $35.41 | 2024 | Barostim Neo System |
| Pfizer INC. | $26.63 | 2019-2020 | |
| Mylan Specialty L.P. | $26.28 | 2023 | Yupelri |
| Abbott Laboratories | $23.59 | 2025 | Mitraclip |
| Teva Pharmaceuticals USA, INC. | $15.42 | 2022 | |
| Sunovion Pharmaceuticals INC. | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gibbons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.